Volumetric reduction and dissolution prediction of monosodium urate crystal during urate-lowering therapy – a study using dual-energy computed tomography

References

• Chhana A, Dalbeth N. The gouty tophus: a review. Curr Rheumatol Rep. 2015;17(3):19.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford). 2007;46(12):1804–7.
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, et al. Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009;36(5):1041–8.
   PubMed Web of Science ®Google Scholar
• Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes. 2012;10(1):117.
   PubMedGoogle Scholar
• Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med. 1966;64(2):229–58.
   PubMed Web of Science ®Google Scholar
• Goldfarb E, Smyth CJ. Effects of allopurinol, a xanthine oxidase inhibitor, and sulfinpyrazone upon the urinary and serum urate concentrations in eight patients with tophaceous gout. Arthritis Rheum. 1966;9(3):414–23.
   PubMedGoogle Scholar
• Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum. 1972;15(2):189–92.
   PubMedGoogle Scholar
• McCarthy GM, Barthelemy CR, Veum JA, Wortmann RL. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum. 1991;34(12):1489–94.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47(4):356–60.
   PubMed Web of Science ®Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology Guidelines for management of Gout. Part 1: Systematic Nonpharmacologic and Pharmacologic Therapeutic Approaches to Hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–46.
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 Updated EULAR evidence-based recommendations for the management of Gout. Ann Rheum Dis. 2017;76(1):29–42.
   PubMed Web of Science ®Google Scholar
• Modjinou DV, Krasnokutsky S, Gyftopoulos S, Pike VC, Karis E, Keenan RT, et al. Comparison of dual-energy CT, ultrasound and surface measurement for assessing tophus dissolution during rapid urate debulking. Clin Rheumatol. 2017;36(9):2101–7.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Aati O, Gao A, House M, Liu Q, Horne A, et al. Assessment of tophus size – a comparison between physical measurement methods and dual-energy computed tomography scanning. J Clin Rheumatol. 2012;18(1):23–7.
   PubMed Web of Science ®Google Scholar
• Araujo EG, Bayat S, Petsch C, Englbrecht M, Faustini F, Kleyer A, et al. Tophus resolution with pegloticase: a prospective dual-energy CT study. RMD Open. 2015;1(1):e000075.
   PubMed Web of Science ®Google Scholar
• Lee YH, Song GG. Diagnostic accuracy of dual-energy computed tomography in patients with gout: a meta-analysis. Semin Arthritis Rheum. 2017;47(1):95–101.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Nicolaou S, Baumgartner S, Hu J, Fung M, Choi HK. Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated by allopurinol. Ann Rheum Dis. 2018;77(3):364–70.
   PubMed Web of Science ®Google Scholar
• Choi HK, Burns LC, Shojania K, Koenig N, Reid G, Abufayyah N, et al. Dual energy CT in gout: a prospective validation study. Ann Rheum Dis. 2012;71(9):1466–71.
   PubMed Web of Science ®Google Scholar
• Ramon A, Bohm-Sigrand A, Pottecher P, Richette P, Maillefert J, Devlilliers H, et al. Role of dual-energy CT in the diagnosis and follow-up of gout: systematic analysis of the literature. Clin Rheumatol. 2018;37(3):587–95.
   PubMed Web of Science ®Google Scholar
• Pascart T, Grandjean A, Norberciak L, Ducoulombier V, Motte M, Luraschi H, et al. Ultrasonography and dual-energy computed tomography provide different quantification of urate burden in gout: results from a cross-sectional study. Arthritis Res Ther. 2017;19(1):171
   PubMedGoogle Scholar
• Chiu MLS, Hu M, Ng MHL, Yeung CK, Chan JC-Y, Chang MM, et al. Association between HLA-B*58:01 allele and severe cutaneous reactions with allopurinol in Han Chinese in Hong Kong. Br J Dermatol. 2012;167(1):44–9.
   PubMed Web of Science ®Google Scholar
• Wolff ML, Cruz JL, Vanderman AJ, Brown JN. The effect of angiotensin II receptor blockers on hyperuricemia. Ther Adv Chronic Dis. 2015;6(6):339–46.
   PubMed Web of Science ®Google Scholar
• Sapsford M, Gamble GD, Aati O, Knight J, Horne A, Doyle AJ, et al. Relationship of bone erosion with the urate and soft tissue components of the tophus in gout: a dual energy computed tomography study. Rheumatology (Oxford). 2017;56(1):129–33.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Lioté F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007;57(7):1324–8.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology 2009;48(suppl 2):ii9–14.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Frampton C, Fung M, Baumgartner S, Nicolaou S, Choi HK. Concurrent validity of provisional remission criteria for gout: a dual-energy CT study . Arthritis Res Ther. 2019;21(1):150–6.
   PubMedGoogle Scholar
• Towiwat P, Chhana A, Dalbeth N. The anatomical pathology of gout: a systematic literature review. BMC Musculoskelet Disord. 2019;20(1):140–53.
   PubMedGoogle Scholar
• Dalbeth N, Aati O, Kalluru R, Gamble GD, Horne A, Doyle AJ, McQueen FM. Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study. Ann Rheum Dis. 2015;74(6):1030–6.
   PubMed Web of Science ®Google Scholar
• Durcan L, Grainger R, Keen HI, Taylor WJ, Dalbeth N. Imaging as a potential outcome measure in gout studies: a systematic literature review. Semin Arthritis Rheum. 2016;45(5):570–9.
   PubMed Web of Science ®Google Scholar
• Mandell BF, Yeo AE, Lipsky PE. Tophus resolution in patient with chronic refractory gout who have persistent urate-lowering responses to pegloticase. Arthritis Res Ther. 2018;20(1):286.
   PubMedGoogle Scholar
• Ellmann H, Bayat S, Araujo E, Manger B, Kleyer A, Cavallaro A, et al. Effects of conventional uric acid-lowering therapy on monosodium urate crystal deposits. Arthritis Rheumatol. 2020;72(1):150–6.
   PubMed Web of Science ®Google Scholar
• Tana C, Ticinesi A, Prati B, Nouvenne A, Meschi T. Uric acid and cognitive function in older individuals. Nutrients 2018;10(8):975.
   Web of Science ®Google Scholar
• Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, Tonelli M. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum. 2013;43(3):367–75.
   PubMed Web of Science ®Google Scholar
• White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–10.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: the “dirty dish” hypothesis. Arthritis Rheumatism. 2011;63(12):4002–6.
   PubMedGoogle Scholar
• Barrera CA, López-López CO, Álvarez-Hernández E, Peláez-Ballestas I, Gómez-Ruiz C, Burgos-Vargas R, et al. Are target urate and remission possible in severe gout? A five-year cohort study. J Rheumatol. 2020;47(1):132–9.
   PubMed Web of Science ®Google Scholar
• Coburn BW, Mikuls TR. The problem with gout is that It's Still Such a Problem. J Rheumatol. 2016;43(8):1453–5.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatoly (Oxford) 2009;48(S2):9–14.
   Google Scholar
• Perez-Ruiz F, Moreno-Lledó A, Urionagüena I, Dickson AJ. Treat to target in gout. Rheumatology (Oxford). 2018;57(suppl_1):i20–i26.
   PubMedGoogle Scholar
• Scheepers LEJM, van Onna M, Stehouwer CDA, Singh JA, Arts ICW, Boonen A. Medication adherence among patients with gout: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018;47(5):689–702.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11(2):R46.
   PubMed Web of Science ®Google Scholar
• Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010;6(4):263–71.
   PubMedGoogle Scholar
• Rashid N, Coburn BW, Wu Y-L, Cheetham TC, Curtis JR, Saag KG, Mikuls TR. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol. 2015;42(3):504–12.
   PubMed Web of Science ®Google Scholar
• Chhana A, Lee G, Dalbeth N. Factors influencing the crystallization of monosodium urate: a systematic literature review. BMC Musculoskelet Disord. 2015;16:296–306.
   PubMed Web of Science ®Google Scholar